Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow DYNAVAX TECHNOLOGIES CORP

Get SEC filing alerts via email and in your feed for DYNAVAX TECHNOLOGIES CORP

DVAX

DYNAVAX TECHNOLOGIES CORP

About DYNAVAX TECHNOLOGIES CORP

Dynavax Technologies is a biopharmaceutical company specializing in developing and commercializing innovative vaccines. Its core product, HEPLISAV-B, is a two-dose hepatitis B vaccine utilizing proprietary CpG 1018 adjuvant technology. The company focuses on vaccines for infectious diseases, leveraging its adjuvant platform to enhance immune responses. It targets adult markets globally, emphasizing vaccine innovation, pipeline expansion, and strategic collaborations to address unmet medical needs.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from DYNAVAX TECHNOLOGIES CORP

1
1
DYNAVAX TECHNOLOGIES CORP Dynavax Technologies Reports 17.7% Revenue Growth in Q3 2025

Via official filing (AI summary) | 8 months ago | 0 comments

2
1
DYNAVAX TECHNOLOGIES CORP Dynavax Technologies Reports 29% Revenue Growth to $95.4 Million in Q2 2025

Via official filing (AI summary) | 11 months ago | 0 comments

3
1
DYNAVAX TECHNOLOGIES CORP Dynavax Technologies Reports 34% Revenue Growth to $68.2 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

4
1
DYNAVAX TECHNOLOGIES CORP Dynavax Technologies Reports 19% Revenue Growth to $277.2 Million for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

5
1
DYNAVAX TECHNOLOGIES CORP Dynavax Technologies Reports 16% Revenue Growth, Net Income Turnaround in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments